Quoin Pharmaceuticals, Ltd.
QNRX
$5.91
-$0.16-2.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.48% | 7.77% | 4.33% | -0.40% | -2.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.97% | 51.75% | 41.90% | 21.70% | 1.60% |
| Operating Income | -70.97% | -51.75% | -41.90% | -21.70% | -1.60% |
| Income Before Tax | -76.34% | -58.23% | -47.01% | -24.21% | -3.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.34% | -58.23% | -47.01% | -24.21% | -3.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.34% | -58.23% | -47.01% | -24.21% | -3.18% |
| EBIT | -70.97% | -51.75% | -41.90% | -21.70% | -1.60% |
| EBITDA | -71.72% | -52.32% | -42.40% | -21.98% | -1.66% |
| EPS Basic | 73.99% | 77.02% | 78.25% | 80.56% | 77.22% |
| Normalized Basic EPS | 73.99% | 77.02% | 78.25% | 80.56% | 77.22% |
| EPS Diluted | 74.02% | 77.04% | 78.16% | 80.50% | 77.18% |
| Normalized Diluted EPS | 73.99% | 77.02% | 78.25% | 80.56% | 77.22% |
| Average Basic Shares Outstanding | 708.09% | 414.94% | 473.96% | 627.71% | 412.45% |
| Average Diluted Shares Outstanding | 715.44% | 416.82% | 475.68% | 629.27% | 413.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |